3-氯-4-(异丙基磺酰基)噻吩-2-羧酸 | 175202-26-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-氯-4-(异丙基磺酰基)噻吩-2-羧酸
• 英文名称: 3-chloro-4-(propane-2-sulfonyl)thiophene-2-carboxylic acid
• 英文别名: 3-Chloro-4-(isopropylsulfonyl)thiophene-2-carboxylic acid；3-chloro-4-propan-2-ylsulfonylthiophene-2-carboxylic acid
• CAS: 175202-26-3
• 化学式: C₈H₉ClO₄S₂
• 分子量: 268.742
• InChiKey: YBTCUNQIEVRDNE-UHFFFAOYSA-N

物化性质

• 沸点：
  484.0±45.0 °C(Predicted)
• 密度：
  1.505±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-氯-4-(异丙基磺酰基)噻吩-2-羧酸 、 4-{2-[1-methyl-4-(1-methyl-4-(4-amino-2-pyrrolecarboxamido)-2-pyrrolecarboxamido)-2-pyrrolecarboxamido]ethyl}morpholine dihydrochloride 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 4-{2-[1-methyl-4-(1-methyl-4-(1-methyl-4-(3-chloro-4-(propane-2-sulfonyl)thiophene-2-carboxamido)-2-pyrrolecarboxamido)-2-pyrrolecarboxamido)-2-pyrrolecarboxamido]ethyl}morpholine
  参考文献：
  名称：

  DNA Binding Ligands Targeting Drug-Resistant Bacteria:  Structure, Activity, and Pharmacology

  摘要：

  We describe the lead optimization and structure-activity relationship of DNA minor-groove binding ligands, a novel class of antibacterial molecules. These compounds have been shown to target A/T-rich sites within the bacterial genome and, as a result, inhibit DNA replication and RNA transcription. The optimization was focused on N-terminal aromatic heterocycles and C-terminal amines and resulted in compounds with improved in vivo tolerability and excellent in vitro antibacterial potency (MIC greater than or equal to 0.031 mug/mL) against a broad range of Grainpositive pathogens, including drug-resistant strains such as methicillin-resistant Stapylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant Enterococcus faecalis (VRE). In a first proof-of-concept study, a selected compound (35) showed in vivo efficacy in a mouse peritonitis model against methicillin-sensitive S. aureus infection with an ED50 value of 30 mg/kg.

  DOI：

  10.1021/jm030097a

文献信息

• Substituted Cyclohexylmethyl Compounds
  申请人：OBERBOERSCH Stefan

  公开号：US20090286833A1

  公开（公告）日：2009-11-19

  Novel cyclohexylmethyl compounds corresponding to formula I wherein R 1 , R 2 , R 3 , R 4 and R 5 , have the meanings given in the description. Pharmaceutical formulations containing these compounds, as well as a processes for preparing these compounds and related methods of treatment are also provided.

  新型环己基甲基化合物对应于式I，其中R1、R2、R3、R4和R5在描述中给出了它们的含义。还提供了含有这些化合物的药物配方，以及制备这些化合物的过程和相关治疗方法。
• Amide substituted xanthine derivatives
  申请人：——

  公开号：US20040014766A1

  公开（公告）日：2004-01-22

  The present invention is a 1,3,8 substituted xanthine derivative of formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and R 3 are as defined in the specification. Compounds of formula I and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.

  本发明是一种具有如下结构的1,3,8取代黄嘌呤衍生物（I1）或其药学上可接受的盐，其中R1、R2和R3如规范中定义。公式I的化合物及其药学上可接受的盐或前药显示出作为糖异生调节剂的活性。
• [EN] AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY<br/>[FR] DERIVES DE XANTHINE A SUBSTITUTION AMIDE A ACTIVITE DE MODULATION DE LA GLUCONEOGENESE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003106459A1

  公开（公告）日：2003-12-24

  The present invention is a 1,3,8 substituted xanthine derivative of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.

  本发明是一种式（I）的1,3,8取代黄嘌呤衍生物或其药用盐，其中R1、R2和R3如规范中所定义。式（I）化合物及其药用盐或前药显示为糖异生调节剂的活性。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20100286126A1

  公开（公告）日：2010-11-11

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 and R 3 are as defined herein.

  化合物的公式（I）或其立体异构体或药用可接受的盐，以及它们的制备和用途作为药物，其中R1、R2和R3如本文所定义。
• REMEDIAL AGENT FOR VIRAL INFECTIOUS DISEASE
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1403269A1

  公开（公告）日：2004-03-31

  A pyridine ring-containing benzoxazinone derivative or a pharmaceutically acceptable salt or tautomer thereof represented by general formula (1): (wherein R1 to R6 and n are as defined in the description) has excellent inhibitory activity against a protease. Thus, the benzoxazinone derivative or a pharmaceutically acceptable salt thereof is useful as an active ingredient for a therapeutic agent for virus infections, particularly herpes virus infections.

  一种含有吡啶环的苯并噁唑酮衍生物或其药用可接受的盐或互变异构体，由通式（1）表示：（其中R1至R6和n如描述中定义）对蛋白酶具有出色的抑制活性。因此，该苯并噁唑酮衍生物或其药用可接受的盐可作为抗病毒治疗剂的活性成分，特别是对疱疹病毒感染。